Attachirent II - Page 3 
"Specific exceptions to the prohibiticxis may be approved by the 
Director, NIH (Section I-D). The Director will consider requests for excep- 
tions frcxn individuals, institutions or corporations regardless of v^ether 
the ^plicant is affiliated with or supported by NIH. Such exceptions will 
generally be approved for specified levels of physical and biological 
containment. " 
This will be followed by a listing of those exceptions v^ich are 
presently authorized and the containment levels approved for the excepted 
experiments. 
4) Part IV of the NIH Guidelines shall be eliminated, with the following 
exceptions: 
(a) Those definitions listed in Part IV-C which may be needed 
clarify statements made elsev^re in the Guidelines shall be 
retained. 
(b) Those portions of Part IV-E defining the composition of RAC 
and prescribing rules for RAC procedures shall be retained. 
(c) The following statement shall be added; 
"Each institution conducting or sponsoring recombinant 
EWA research should take responsibility for monitoring its own 
activities in this area. Any unusual events that might be 
associated with the use of recombinant ENA molecules should be 
reported to the Director, NIH." 
5) Section VI of the Guidelines will be eliminated, except for those 
portions of Section VI-F relevant to the protecticxi of proprietary infor- 
mation submitted in support of requests for exceptions from the prohibitions. 
[ 228 ] 
